Showing results (41-50 of 584) with videos related to
Sort By:
Pageof 59
Cancer|April 2, 2025
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practiceClaudia Parisi, David PlanchardJTO Clinical and Research Reports|June 19, 2025
Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]Mariona Riudavets, David PlanchardTherapeutic Advances in Respiratory Disease|October 28, 2016
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experienceIvana Sullivan, David PlanchardCancer Management and Research|February 7, 2018
The role of brigatinib in crizotinib-resistant non-small cell lung cancerLaura Mezquita, David PlanchardClinical Advances in Hematology & Oncology : H&O|November 4, 2022
Ongoing progress in BRAF-mutated non-small cell lung cancerPamela Abdayem, David PlanchardJAMA Oncology|June 12, 2020
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung CancerBaptiste Kas, Hugues Talbot, Roberto Ferrara, et al.Expert Review of Molecular Diagnostics|November 14, 2015
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancerKirsty Ross, Emma Pailler, Vincent Faugeroux, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2023
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural MesotheliomaMarco Tagliamento, Massimo Di Maio, Jordi Remon, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinomaNader Abedallaa, Lise Tremblay, Charlotte Baey, et al.Cancer Treatment Reviews|September 10, 2023
Local control strategies for management of NSCLC with oligoprogressive diseaseAntoine Mavrikios, Jordi Remon, Clément Quevrin, et al.Pageof 59